Clinical Trials Directory

Trials / Completed

CompletedNCT00222092

Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers

Effect of Octreotide, Somatostatin, Pentoxyfilline or Placebo in the Prevention and the Course of Post-ERCP Pancreatitis and Study of Molecular Markers in Post-ERCP Pancreatitis

Status
Completed
Phase
Study type
Observational
Enrollment
300 (planned)
Sponsor
University of Ioannina · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Octreotide, somatostatin and pentoxyfilline commercially available drugs that are used in various clinical situations. They are safe and known for years. Octreotide and somatostatin have been used in many studies for the prophylaxis and treatment of pancreatitis and post-ERCP pancreatitis, while pentoxyfilline has shown effect on patients with alcoholic hepatitis, obstructive vasculitis etc. The aim of the study is to evaluate the efficacy of any of those treatments for the prophylaxis and treatment of post-ERCP pancreatitis. In addition some molecular markers of acute and chronic inflammation will be measured before and after the endoscopic procedures according to the study protocol.

Conditions

Timeline

Start date
2005-09-01
Completion
2006-09-01
First posted
2005-09-22
Last updated
2011-08-24

Locations

1 site across 1 country: Greece

Source: ClinicalTrials.gov record NCT00222092. Inclusion in this directory is not an endorsement.

Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers (NCT00222092) · Clinical Trials Directory